MAIA BIOTECHNOLOGY INC
MAIANYSE AMERICAN🏆 #3108 by market capEarnings Nov 5US Equity
$453.16▲ $3.67 (+0.81%)
Simulated price1h—
24h▲ 0.8%
7d▲ 32039.0%
14d▲ 37663.3%
30d▲ 32039.0%
1y▲ 28948.7%
🏦Market Cap
$84M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $450.33 – $458.63
- 52-Week Range
- $0.87 – $3.19
- Volume
- $3.02B
- Avg Volume
- $3.01B
- Shares Outstanding
- 60.8M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.68
- Dividend Yield
- —
Why Investors Own MAIA
- ✓High-growth profile — revenue up -3.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5M▼ −6.8% YoY
Gross Margin (TTM)
26.7%▲ +3.1% YoY
Operating Income (TTM)
$970,977▼ −6.8% YoY
Free Cash Flow (TTM)
$506,596▼ −6.8% YoY
About MAIA BIOTECHNOLOGY INC
A company profile for MAIA BIOTECHNOLOGY INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Price Target
ⓘAverage Target
$458.48
▲ +1.2% Upside
High Target$549.64
Low Target$399.75
Based on 20 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
MAIA BIOTECHNOLOGY INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift MAIA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
MAIA BIOTECHNOLOGY INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.